This article is more than 5 years old. Information may no longer be current.
ITPC results incomplete; no link between CYP2D6 and tamoxifen outcome
Click Here to Manage Email Alerts
There was no association between CYP2D6 genotype and invasive DFS among women with early stage, ER-positive breast cancer treated with adjuvant tamoxifen.
Matthew P. Goetz, MD, associate professor of oncology at the Mayo Clinic in Rochester, Minn., recently presented findings from the International Tamoxifen Pharmacogenomics Consortium.
The goal of the ITPC was to investigate the conflicting relationship between CYP2D6 genotype/phenotype and clinical outcome of tamoxifen in women with ER-positive breast cancer. Medication data was also investigated. Identification of the predictive value of CYP2D6 might enable the identification of patients who may be spared ineffective tamoxifen therapy.
Primary analysis was modified due to incomplete medication data; therefore, data was in regard to only CYP2D6 phenotype. Data from 2,880 patients from six sites were analyzed.
“The ITPC demonstrated no association of CYP2D6 genotype of invasive DFS or OS in women receiving adjuvant tamoxifen; however, our primary analysis, which was to analyze both CYP2D6 genotype plus medication data, was not possible and was abandoned due to incomplete medication data,” Goetz said. Given that many patients had incomplete genotyping, received varying doses and varying duration of tamoxifen, final conclusions are not possible at this time.
For more information:
- Goetz MP. #33.